Aspergillosis Weekly Research Update

Inhaled itraconazole shows promise for ABPA
Week ending 21 July 2026
This week brought encouraging early results for an inhaled form of itraconazole,
alongside new research into chronic pulmonary aspergillosis (CPA), lung surgery
and the effects of influenza on our antifungal immune defences.
Paper of the week: inhaled itraconazole for ABPA
A phase 2 clinical trial has produced promising results for an inhaled form of
itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis
(ABPA).
Itraconazole is normally taken by mouth. It can help reduce the amount of
Aspergillus in the airways, but oral treatment can cause side effects,
interact with other medicines and produce unpredictable drug levels.
PUR1900 is a dry-powder form of itraconazole designed to deliver the drug
directly into the lungs. The aim is to produce higher concentrations in the
airways while reducing the amount of itraconazole circulating through the rest
of the body.
What did the trial find?
The trial included 43 adults with asthma and ABPA. Participants received either
20 mg or 40 mg of inhaled itraconazole, or a placebo, once daily for 16 weeks.
Compared with placebo, people receiving the 40 mg dose experienced:
- An average placebo-adjusted improvement in FEV1 of approximately 0.28 litres.
- Better asthma-control questionnaire scores.
- A reduction in total IgE, a marker associated with allergic activity.
- No serious adverse events during the trial.
The lower 20 mg dose did not produce the same pattern of improvement.
What does this mean?
These are encouraging results because delivering itraconazole directly into the
lungs could potentially reduce some of the toxicity and drug interactions
associated with oral treatment.
However, this was a small exploratory study. Only nine participants received
placebo, and the study did not have one prespecified primary outcome against
which success or failure would be judged. The results therefore need confirmation
in a larger phase 3 trial before inhaled itraconazole could become a routine
treatment for ABPA.
PUR1900 remains an investigational treatment and is not currently available on
prescription.
Chronic pulmonary aspergillosis and sarcoidosis
A new clinical review examines the difficult relationship between pulmonary
sarcoidosis and chronic pulmonary aspergillosis.
Advanced sarcoidosis can cause fibrosis, cavities and structural changes in the
lungs. These damaged areas may provide an opportunity for Aspergillus
to grow and CPA to develop.
The two conditions can be difficult to separate because both may cause:
- Increasing breathlessness.
- Persistent coughing.
- Fatigue and weight loss.
- Changes on chest scans.
- Declining lung function.
This creates an important treatment dilemma. Corticosteroids and other
immune-suppressing medicines may be needed to control active sarcoidosis, but
they can also make fungal infection more difficult to control.
The practical message is that deterioration in someone with fibrotic or cavitary
sarcoidosis should not automatically be assumed to represent worsening
sarcoidosis. CPA may need to be investigated before immunosuppressive treatment
is increased.
This article is a review of existing evidence rather than a new clinical trial,
but it draws attention to an important and sometimes overlooked association.
Could smaller operations preserve more lung in CPA?
Surgery can sometimes remove localised CPA, particularly a simple aspergilloma
or an affected part of the lung causing repeated bleeding. Surgery is not
suitable for everyone because many people with CPA already have reduced lung
function or extensive underlying lung disease.
A 15-year study examined 151 people with CPA who underwent video-assisted
thoracoscopic surgery, commonly called keyhole lung surgery. Researchers compared
removal of an entire lung lobe with smaller, sublobar resections that preserved
more healthy lung tissue.
People receiving a smaller resection experienced less loss of lung function.
Overall complication rates were similar in the two surgical groups, as were the
observed recurrence rates. Across all participants with sufficient follow-up,
CPA recurred in approximately 11%.
CPA operations remained more technically difficult than comparable lung-cancer
surgery. Severe adhesions and lesions larger than 3 cm were associated with a
greater risk of postoperative complications.
The study suggests that a lung-sparing operation may be possible for carefully
selected people with localised disease. It does not prove that a smaller operation
is suitable for everyone: the study was retrospective, conducted at one centre
and did not randomly assign people to the different surgical approaches.
Research corner: why can influenza increase the risk of aspergillosis?
Influenza-associated pulmonary aspergillosis, or IAPA, is a serious complication
that can develop in people admitted to intensive care with severe influenza.
It can occur even when someone did not previously have the traditional risk
factors for invasive fungal infection.
Two linked laboratory studies have investigated how influenza changes the immune
environment inside the lungs.
One study found widespread changes in lung immune cells, including functional
problems in particular groups of neutrophils. Neutrophils normally play a central
role in recognising and killing invading Aspergillus.
The second study examined a signalling molecule called interleukin-27, or IL-27.
Its results suggest that IL-27 may help protect against IAPA by limiting an
unhelpful type-2 immune response while strengthening antifungal activity.
Together, the studies help explain why recovery from influenza is not simply a
return to normal immunity. The infection can leave temporary defects in the
lungs’ ability to control fungi.
These studies used experimental models and have been released as preprints,
meaning they have not yet completed formal peer review. They do not currently
change how IAPA is diagnosed or treated.
What are this week’s main messages?
- Inhaled itraconazole produced promising improvements in a small phase 2 ABPA
trial, particularly at the higher dose. - Larger trials are required before inhaled itraconazole can become a routine
treatment. - CPA should be considered when someone with fibrotic or cavitary sarcoidosis
experiences unexplained deterioration. - Smaller lung resections may preserve more lung function in carefully selected
people with localised CPA. - Influenza can disrupt several parts of the lung’s antifungal immune response,
helping to explain the development of IAPA.
Speaking up about your healthcare: self-advocacy and independent advocacy

Last reviewed: July 2026
If you have concerns about how your condition is being investigated or managed, it can sometimes feel difficult to make yourself heard. This may be especially challenging with a rare condition such as aspergillosis, where healthcare professionals outside specialist services may have limited experience of the disease.
Advocacy means helping your views, questions and wishes to be understood. You may be able to advocate for yourself, ask a trusted person to support you, or use an independent advocacy service.
Speaking up does not mean being confrontational. It means working with your healthcare team to understand your care, participate in decisions and raise concerns when something does not seem right.
Before an appointment
A little preparation can make it easier to explain what matters most to you.
- Write down your two or three most important questions.
- Make a brief timeline of new symptoms, treatment changes or important events.
- Bring an up-to-date medication list, including inhalers, steroids, supplements and non-prescription medicines.
- Record how the condition is affecting everyday life, not only individual symptoms.
- Decide what you hope will happen next—for example, a clearer explanation, a medication review or a follow-up plan.
- Ask whether a family member, friend or carer can attend with you.
You can say at the beginning of the appointment:
“I have three things I particularly need to understand today. Can we make sure we cover them before the appointment ends?”
Questions you are entitled to ask
You can ask your healthcare professional to explain:
- what diagnosis they think you have and how certain they are;
- what your test or scan results mean;
- what the available treatment options are;
- the expected benefits, risks and side effects of treatment;
- what monitoring will be needed;
- what alternatives are available;
- what might happen if you decide not to have a treatment;
- who to contact if symptoms or side effects worsen;
- when your condition and treatment will next be reviewed.
If an explanation is unclear, it is reasonable to ask for it to be repeated in plain language. Before leaving, try to confirm the plan:
“Can I check that I have understood? The next step is … and I should contact … if … happens.”
Contacting your clinical team between appointments
Your clinic letter or hospital correspondence may include contact details for the consultant’s secretary or specialist nursing team. When contacting them:
- include your full name, date of birth and NHS number if known;
- briefly explain the problem and when it began;
- state whether it is getting worse;
- say what response you need—for example, advice, an earlier review or clarification of the treatment plan;
- keep a record of when you contacted the service.
Email can be useful because it creates a written record, but it may not be monitored continuously. If the matter is urgent, follow the urgent-care instructions provided by your clinical team rather than relying on email.
If you are deaf, have hearing loss or find telephone communication difficult, ask the service to record your communication needs and offer an accessible way to contact you. You may also be able to use Relay UK, which replaced the former Next Generation Text Service.
Ask someone you trust to support you
A family member, friend or carer can:
- help you prepare questions;
- take notes during an appointment;
- remind you about points you wanted to raise;
- help explain how the condition affects you at home;
- support you emotionally;
- help follow up agreed actions afterwards.
Healthcare professionals will normally need your permission before discussing confidential information with another person. Tell the team clearly if you want somebody involved and ask how your consent should be recorded.
Your supporter should help communicate your wishes rather than make decisions for you unless they have the appropriate legal authority.
If you are worried that something has been missed
Explain your concern as specifically as possible. For example:
“My symptoms have become worse despite following the treatment plan. I am concerned that something may have changed. Could you explain what has been ruled out and whether I need further assessment?”
You can ask whether your case should be discussed with another clinician, reviewed by a multidisciplinary team or referred for specialist advice. You can also ask about a second opinion, although access and referral arrangements vary and there is not always an automatic right to one.
Do not wait for a routine complaints process if you develop severe or rapidly worsening symptoms. Use the urgent contact instructions provided by your healthcare team, NHS 111 or emergency services as appropriate.
Contacting PALS
If you cannot resolve a concern directly with the clinical team, contact the Patient Advice and Liaison Service at the hospital providing your care.
PALS can:
- help resolve concerns informally;
- explain how the hospital’s services work;
- help identify the right person or department to contact;
- provide information about the NHS complaints process;
- tell you where to find independent support.
PALS is part of the NHS organisation, so it is helpful for resolving problems but is not the same as an independent advocate.
What is an independent advocate?
An independent advocate can help you understand information, communicate your views and participate in decisions about your care. Depending on the service and your circumstances, an advocate may:
- help you prepare for meetings or assessments;
- help you write letters or make phone calls;
- attend meetings with you;
- help you understand different options;
- support you during a complaint.
An advocate does not make decisions for you, provide medical advice or tell you what choice to make.
In some circumstances, a local council must arrange advocacy for a person who has substantial difficulty understanding or participating in decisions and has nobody appropriate to support them. The NHS provides more information about finding someone to speak up for you.
Finding an advocate
Advocacy provision varies between areas. Possible starting points include:
- your local council’s adult social care service;
- the hospital’s PALS team;
- your local Healthwatch;
- an independent NHS complaints advocacy provider;
- disability or condition-specific organisations.
You can find your local Healthwatch and ask which organisation currently provides advocacy in your area.
Named advocacy providers change between areas and over time, so it is safer to check locally rather than assume that one national organisation covers your location.
If informal efforts do not resolve the problem
Keep a brief written record of:
- what happened;
- the dates of appointments and contacts;
- who you spoke to;
- what was agreed;
- what remains unresolved;
- what outcome you are seeking.
If direct discussion and PALS do not resolve the concern, you can use the NHS complaints process. In England, free NHS complaints advocacy may be available to help you prepare a complaint and attend meetings. NHS England provides information about feedback and complaints about NHS services.
If you reach the end of the NHS complaints process in England and remain dissatisfied, you may be able to ask the Parliamentary and Health Service Ombudsman to review the complaint.
Complaints and advocacy arrangements differ in Scotland, Wales and Northern Ireland, so use the health-service guidance for the country in which you receive care.
Being persistent without carrying the whole burden yourself
If an important question remains unanswered, follow up calmly and clearly. Refer to previous contacts, explain why the issue matters and state what response you need.
However, patients should not have to manage complex healthcare systems entirely alone. If repeated attempts are getting nowhere, involve PALS, your GP, an independent advocate or another appropriate service rather than feeling that you simply have to “push harder”.
A simple advocacy checklist
- What is my main concern?
- What evidence or examples can I provide?
- What do I need explained?
- What outcome am I asking for?
- Who is responsible for the next action?
- When should I expect a response?
- Who can support me if the problem remains unresolved?
Important: This information is primarily about NHS care in England. It provides general guidance and is not a substitute for individual medical or legal advice. Seek urgent medical help if symptoms are severe or rapidly worsening.
Carriers of cystic fibrosis may be at greater risk for allergic bronchopulmonary aspergillosis

Research suggests that some variants in the CFTR gene may be more common among people with allergic bronchopulmonary aspergillosis (ABPA). However, the connection remains uncertain, and carrying one CFTR variant does not mean that someone has cystic fibrosis.
Reviewed and updated: 22 July 2026
What is the CFTR gene?
The CFTR gene provides instructions for making a protein that helps regulate the movement of salt and water across cell surfaces. This contributes to keeping mucus in the lungs and other organs at the correct consistency.
Cystic fibrosis (CF) is usually caused by disease-causing variants in both copies of the CFTR gene—one inherited from each parent. A person with only one disease-causing variant is generally described as a CF carrier and does not have cystic fibrosis.
Nevertheless, research increasingly suggests that some carriers may have a slightly greater susceptibility to certain respiratory conditions. This does not mean that every carrier will develop lung disease.
What did the original ABPA study find?
Researchers at the National Aspergillosis Centre and Manchester Centre for Genomic Medicine studied 156 people with ABPA who underwent genetic screening.
They reported that 18 people—11.5% of the group—had at least one detected CFTR variant. This was higher than the estimated carrier frequency used for comparison at the time. Two patients had variants in both copies of the gene and were subsequently diagnosed with cystic fibrosis.
The researchers suggested that CFTR testing and genetic counselling might be appropriate for selected people with ABPA.
However, this was a retrospective study conducted at a specialist referral centre. The genetic tests used did not identify every possible CFTR variant, and the study could not establish that carrying one variant caused ABPA.
Read the original study in the Journal of Asthma.
What has newer research found?
A large genomic study published in 2025 examined health conditions among people carrying one disease-causing CFTR variant. ABPA was observed more frequently among carriers, with an estimated odds ratio of 2.50.
That result needs careful interpretation. ABPA was uncommon, and the association did not remain statistically significant after the researchers accounted for the large number of conditions being investigated. The study’s overall analysis did not find conclusive evidence that CFTR carriers had an increased risk across the range of cystic-fibrosis-associated conditions.
The researchers also noted that some earlier studies recruited patients who were already receiving specialist care or genetic testing. This can create selection bias: the people included may not be representative of carriers in the wider population.
Read the 2025 study in JAMA Internal Medicine.
Other recent research indicates that CF carriers who develop bronchiectasis may experience more severe disease or particular respiratory infections. These findings support further investigation of CFTR function in chronic lung disease, but they do not prove that carrier status causes bronchiectasis or ABPA.
Read the 2024 study of CF carriers with bronchiectasis.
Should everyone with ABPA have CFTR testing?
Current international ABPA guidance does not recommend routine CFTR genetic testing for every person with ABPA.
A respiratory specialist may consider investigating cystic fibrosis or a CFTR-related disorder when other clinical features raise suspicion. These might include:
- bronchiectasis beginning unusually early in life;
- recurrent or persistent respiratory infections;
- repeated isolation of organisms commonly associated with cystic fibrosis;
- chronic sinus disease or nasal polyps;
- digestive problems or pancreatic insufficiency;
- male infertility caused by congenital absence of the vas deferens;
- a family history of cystic fibrosis; or
- previous genetic results that require further interpretation.
Depending on the circumstances, assessment could include a sweat test, genetic testing and referral to a cystic fibrosis or clinical genetics service.
Read the revised international guidance on diagnosing and treating ABPA.
What does a positive genetic result mean?
Finding one CFTR variant does not automatically explain a person’s ABPA, establish a diagnosis of cystic fibrosis or indicate that their treatment should change.
There are thousands of known CFTR variants, and they do not all have the same effects. Results need to be interpreted alongside symptoms, medical history, sweat-test results and other clinical findings.
Genetic counselling can help people understand what a result means for them and whether it has implications for relatives or future children.
Does CF carrier status change ABPA treatment?
There is currently no evidence that someone should receive antifungal treatment, corticosteroids, biologic treatment or a CFTR modulator solely because they carry one CFTR variant.
ABPA treatment should continue to be based on the person’s symptoms, test results, lung imaging, underlying condition and response to treatment. CFTR modulators are approved for eligible people with cystic fibrosis; they are not an established treatment for ABPA in people who do not have CF.
The current position
CFTR variants may contribute to respiratory susceptibility in some people with ABPA, but the size and clinical importance of the association remain uncertain. More prospective research involving representative patient groups is needed.
If you have ABPA and are concerned about cystic fibrosis or a genetic test result, discuss this with your specialist team. They can decide whether further assessment or genetic counselling would be useful in your particular circumstances.
This information is intended for general education and does not replace individual medical advice.
Your Story Matters—but It Is Not Someone Else’s Future

Being diagnosed with aspergillosis can be frightening. Many people turn to support groups hoping to meet others who understand, learn what treatment is like and discover how people manage everyday life.
Hearing from someone who has lived through the same illness can provide something that medical information alone cannot: recognition, practical experience and the reassurance that you are not facing it alone.
But there is an important distinction between sharing an experience and predicting another person’s future.
“This happened to me” can be helpful.
“This is what you have ahead of you” may not be true.
Aspergillosis does not follow one path
The word aspergillosis covers several very different conditions. These include allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), Aspergillus bronchitis, aspergilloma and invasive aspergillosis.
They do not have the same causes, treatments or likely outcomes. The US Centers for Disease Control and Prevention notes that different forms of aspergillosis have different symptoms and treatments.
Even people with the same form of aspergillosis can have very different experiences. Their health may be influenced by:
- the extent of their lung disease;
- asthma, bronchiectasis or another underlying condition;
- immune function and other health problems;
- how early the disease was recognised;
- response to antifungal or other treatment;
- side effects and tolerance of medicines;
- access to specialist care.
One person’s course—whether difficult or relatively straightforward—cannot reliably tell us what will happen to another.
For more information about how the different conditions compare, see our guide to the different forms of aspergillosis.
Why support groups can sometimes appear frightening
Support groups perform an enormously valuable role. Research across a range of health conditions shows that peer support can reduce isolation, provide practical knowledge and help people cope with illness.
However, the conversations in a support group do not necessarily represent everyone living with the condition.
People are particularly likely to seek help when they are newly diagnosed, experiencing symptoms, having treatment difficulties or feeling worried. Those who are stable or getting on with their lives may have less reason to post regularly. This can make the most complicated experiences especially visible.
Several people describing serious difficulties does not necessarily mean that everyone—or even most people—with the condition will experience the same course.
This does not make those difficult stories any less real. It simply means that they should not be treated as a forecast for somebody else.
Difficult experiences deserve to be heard
People who have endured years of illness may want to protect others from being unprepared. A warning that sounds pessimistic may come from kindness, frustration or the wish to ensure that another patient is taken seriously.
Nobody should feel pressured to make a difficult experience sound positive. Support groups must remain places where people can speak honestly about fear, deterioration, treatment failures and loss.
But honesty also includes acknowledging uncertainty:
“My illness developed in this way, but yours may not.”
That small qualification can make a great difference to somebody who has only just been diagnosed.
Sharing without predicting
Helpful ways to introduce a personal experience include:
- “This was my experience, although yours may be different.”
- “I have the same diagnosis, but I also have other lung conditions.”
- “This happened to me, so it may be worth asking your doctor about.”
- “Some people experience this, but not everyone does.”
- “Ask your clinical team what they expect in your particular case.”
Try to avoid statements such as:
- “This is what you have ahead of you.”
- “It will inevitably get worse.”
- “That treatment never works.”
- “You will end up in the same position as me.”
The same principle applies to reassuring stories. One person doing very well does not guarantee that another person will have the same result. Peer support should offer experience, companionship and useful questions—not certainty that no individual can provide.
For people who are newly diagnosed
If the stories you encounter feel overwhelming, remember:
- the person speaking may have a different form of aspergillosis;
- they may have additional illnesses or a more complicated clinical history;
- support-group discussions may contain a greater proportion of people currently experiencing problems;
- treatments and clinical knowledge change over time;
- your own healthcare team has information about your tests, scans, medical history and response to treatment.
It is reasonable to ask your healthcare team:
- Which form of aspergillosis do I have?
- How severe does it appear to be?
- What is the purpose of my treatment?
- What improvement or stability are you hoping to achieve?
- What will you monitor?
- Are there particular warning signs I should know about?
These questions can provide more useful information about your likely course than another person’s experience alone.
Making space for every story
A healthy support community needs people who are struggling, people who are improving and people whose condition is stable. It needs realism, but it also needs hope—and neither should be manufactured.
Your experience matters. Sharing it may help someone feel understood, recognise a problem or ask an important question.
But it remains your story, not their prognosis.
The most supportive message we can offer may be:
“I cannot tell you what your future holds, but you do not have to face the uncertainty alone.”
If you would like to meet other people affected by aspergillosis, learn more about our patient support groups and meetings.
Further reading
Research reviews describe both the important benefits and possible challenges of peer support, including emotional support, practical knowledge and reduced isolation, alongside possible risks such as distress spreading between members.
- From Social Network to Peer Support Network: Opportunities and Challenges
- Peer Support in Chronic Conditions: A Systematic Review
- The Benefits and Challenges of Established Peer Support Programmes
This article provides general information and is not a prediction of any individual’s health or a substitute for advice from their healthcare team.
Damp, mould and health in 2026: what we know, what has changed and what people can do

The evidence that damp and mouldy buildings can damage health is now well established.
New research is moving the field forward by measuring the fungi people actually breathe,
examining long-term exposure and mental health, and asking how homes can become more
energy efficient without trapping moisture.
The state of play
Damp and mould are no longer regarded simply as cosmetic housing problems. The
World Health Organization guidelines on indoor dampness and mould
concluded that occupants of damp or mouldy buildings have increased risks of respiratory
symptoms, respiratory infections and worsening asthma.
Since then, large reviews and newer studies have continued to associate damp or mouldy
homes with:
- the development and worsening of asthma;
- wheeze, cough and breathlessness;
- allergic rhinitis and fungal sensitisation;
- respiratory infections, particularly in children;
- hypersensitivity pneumonitis in susceptible people;
- fungal disease in a smaller number of clinically vulnerable people;
- stress, anxiety and poorer mental wellbeing.
These findings describe increased risks across populations. They do not mean that every
person living in a damp home will become ill, or that every symptom occurring in a mouldy
property was necessarily caused by mould.
Nevertheless, the overall evidence is sufficiently strong that public-health advice is to
prevent persistent dampness and remediate mould promptly. Current
UK Government guidance on the health risks of damp and mould
also makes clear that landlords should respond to the presence of damp and mould rather than
waiting for tenants to provide medical proof.
How our understanding has changed
Before 2000: concern but limited measurement
Doctors and housing researchers had long observed that people in damp buildings reported
more respiratory symptoms, but studies used many different definitions of dampness and
mould.
2009: an international evidence benchmark
The WHO reviewed the available evidence and concluded that preventing or minimising
persistent dampness and microbial growth was the most important protective measure.
2010s: stronger epidemiological evidence
Systematic reviews found consistent associations between visible dampness or mould and
asthma, wheeze, cough, respiratory infections and allergic symptoms. A widely cited
review by Mendell and colleagues
helped establish the modern evidence base.
2022–25: damp housing becomes a major UK policy issue
The death of two-year-old Awaab Ishak after prolonged exposure to mould in social housing
transformed public understanding and accelerated legal reform. The first phase of
Awaab’s Law
came into force for social housing in England in October 2025.
2026: measuring the indoor fungal environment
Researchers are now moving beyond questionnaires and visible mould to analyse the mixture
of fungal material present in indoor air. This does not yet provide a routine clinical test,
but it gives a much more detailed picture of exposure.
What has changed in 2026?
Several new papers have added important pieces to the evidence. They do not overturn the
existing consensus. Instead, they begin to answer questions that older research could not.
1. What fungi are people actually breathing inside UK homes?
The most important new UK exposure study was published in The Lancet Microbe by
Samuel Hemmings and colleagues.
The researchers sampled air in 118 West London households, with repeated
sampling across different seasons. They used passive air samplers, DNA sequencing and
quantitative PCR rather than relying only on visible mould or attempting to grow selected
fungi in culture.
Across 262 indoor and outdoor samples, the researchers detected more than
2,000 fungal genera. Indoor fungal communities were significantly richer,
more diverse and more variable between locations than the communities detected at the
outdoor sampling sites. Indoor communities also showed much stronger seasonal cycling.
:contentReference[oaicite:0]{index=0}
Several medically relevant genera, including Aspergillus,
Penicillium and Wallemia, were enriched indoors. Visible mould was
associated with some of the highest total fungal burdens measured in the study.
:contentReference[oaicite:1]{index=1}
Read the original open-access paper: Hemmings SJ et al. Diversity analysis of indoor and outdoor fungal bioaerosols in UK households
.
Visible mould was not the whole story
One of the most clinically interesting observations involved a home in which no visible mould
was found. A child living there had uncontrolled asthma, confirmed Aspergillus
allergy and repeated hospital admissions.
The total fungal burden in that home was close to the study median, but
Aspergillus was unusually prominent and its estimated absolute abundance was among
the highest in the study. :contentReference[oaicite:2]{index=2}
This single household cannot prove that the exposure caused the child’s hospitalisations.
It does, however, show why visual inspection alone cannot describe the full fungal environment
inside a property.
A home can have a potentially important airborne fungal profile even when no large patch of
mould is visible.
What this study does not tell us
This was principally an environmental exposure study, not a clinical trial designed to prove
that particular fungal measurements caused illness.
It does not establish:
- a safe or unsafe numerical threshold for indoor fungal exposure;
- that greater fungal diversity is necessarily harmful;
- that every home should undergo commercial air testing;
- that detecting Aspergillus means someone will develop aspergillosis;
- that one measurement can predict an individual patient’s symptoms.
Its importance is that it establishes a detailed UK baseline and demonstrates methods that
may support better research and surveillance in the future.
2. Long-term exposure and the development of respiratory disease
A second 2026 study examined dampness and mould exposure over approximately 20 years in more
than 8,400 adults participating in the Respiratory Health in Northern Europe
study.
Long-term exposure was associated with the later onset of respiratory symptoms, asthma and
rhinitis. Exposure reported in both the home and workplace appeared more concerning than
exposure in only one setting.
This is important because much of the earlier evidence was based on cross-sectional studies,
which measure housing conditions and health at roughly the same time. Longitudinal research
is better able to establish that exposure occurred before the new health outcome, although it
still cannot remove every possible confounding factor.
3. Damp housing and mental health
The health burden of damp housing is not limited to the lungs. Living with an unresolved
leak, damaged belongings, unpleasant smells, repeated cleaning, disputes over repairs and
fear for a child’s health can be profoundly stressful.
A 2026 analysis published in the American Journal of Epidemiology found an
association between damp housing and psychological distress. The association was stronger
among people who already had a chronic respiratory condition.
This does not establish that inhaled mould directly causes every mental-health effect. Much
of the burden may arise through the combined effects of physical symptoms, housing insecurity,
financial pressure, disrupted sleep, loss of belongings and difficulty obtaining repairs.
4. Flooding and water-damaged buildings
Climate change and more frequent extreme rainfall are increasing interest in the health
consequences of flooded buildings.
A 2026 study in the Journal of Cleaner Production examined new respiratory symptoms
following major flooding. Indoor mould, flood depth, roof condition, ventilation and other
building characteristics emerged as important predictors.
The findings support an established practical principle: after water damage, buildings need
to be dried, assessed and repaired promptly. Simply redecorating a surface while moisture
remains within walls, floors or furnishings may leave the underlying problem unresolved.
5. Can greener and better-insulated homes remain healthy?
Another important 2026 paper approached the problem from building science rather than
medicine.
The open-access review in npj Materials Degradation, part of the Nature Portfolio,
examined the mould susceptibility of bio-based insulation materials used in modern
construction.
Materials made from plant or other biological sources can reduce the environmental impact of
construction. However, because they contain organic material, some can support fungal growth
if they become persistently wet.
The review found that meaningful comparison between products is difficult because laboratory
testing methods vary and do not always reproduce conditions inside real buildings. The authors
called for standardised testing and better long-term evidence from occupied buildings.
Read: Wildman J et al. Mould susceptibility of bio-based insulation materials in modern construction
Energy efficiency and healthy indoor air are not competing goals. Buildings need insulation, moisture control and effective ventilation to be considered together.
What does all of this mean?
The new studies fit together rather than contradicting one another:
- Long-term population studies show that prolonged exposure is associated
with new respiratory disease. - The UK household study shows that indoor fungal communities can differ
greatly from outdoor air and from one home to another. - Mental-health research shows that the consequences extend beyond physical
respiratory symptoms. - Flood research highlights the importance of rapid drying and building repair.
- Building-material research shows that moisture resilience must be included
when homes are insulated or refurbished.
We are therefore moving from a fairly broad conclusion—
damp buildings are associated with poor health—towards more detailed questions:
- Which fungi and other microbial products are present?
- What are their sources?
- How does exposure vary through the year?
- Which people are most susceptible?
- What level and duration of exposure are harmful?
- Which repairs and ventilation interventions produce meaningful health improvements?
Why some people are more vulnerable
Most people inhale fungal spores every day without developing fungal disease. Health effects
depend on the person, the building, the mixture of exposures and the duration of exposure.
Greater caution is appropriate for:
- babies and children;
- people with asthma or severe asthma;
- people sensitised or allergic to fungi;
- people with ABPA;
- people with bronchiectasis, COPD or other chronic lung disease;
- people with CPA or another form of aspergillosis;
- people whose immune system is significantly weakened;
- older people and those with reduced mobility.
For people with asthma, fungal sensitisation or ABPA, exposure may trigger allergic airway
inflammation. In someone with damaged lungs, impaired mucus clearance or substantial immune
suppression, the clinical questions may be different and should be discussed with the
treating team.
Can indoor mould cause aspergillosis?
Aspergillus is common in the wider environment as well as indoors. Detecting it in a
home does not prove that it caused a person’s aspergillosis, and it is usually impossible to
trace an individual infection or allergic response to one particular building.
However, avoiding persistent and unnecessary high exposure is sensible, particularly for
people with fungal allergy, ABPA, damaged lungs or significant immune suppression.
Our guide to reducing exposure to mould and Aspergillus at home
explains practical steps without suggesting that a home can or should be made completely
free of fungal spores.
Should you buy a home mould test?
Routine commercial testing is not normally the first or most useful response to visible damp
or mould.
There are currently no universally accepted health-based numerical limits for total indoor
fungal bioaerosols. A sample may also vary according to the room, season, weather, sampling
method and activity in the home.
A result showing that fungi are present does not by itself establish:
- that the level is dangerous;
- that the fungi caused a particular illness;
- where the moisture is entering the building;
- what repair is required.
Where damp, leaks, condensation or mould are already apparent, the priority is usually a
competent inspection of the building and correction of the moisture source.
What to do if your home is damp or mouldy
- Record the problem. Photograph visible mould, staining, condensation, leaks
and damaged possessions. Record dates, affected rooms and previous reports. - Report it in writing. Tenants should notify their landlord or housing
provider and keep copies of messages and repair reports. - Ask for the underlying cause to be investigated. Possible causes include
plumbing or roof leaks, penetrating or rising damp, inadequate insulation, cold bridges,
defective extraction and insufficient ventilation. - Explain relevant health vulnerabilities. State clearly when a household
member has asthma, chronic lung disease, fungal allergy, aspergillosis, immune suppression
or another condition that may increase risk. - Reduce moisture where reasonably possible. Use working extractor fans,
ventilate after bathing or cooking, avoid blocking air vents and dry wet materials promptly. - Do not accept repeated surface treatment as a permanent repair. Cleaning or
painting may remove visible growth temporarily but will not solve an ongoing moisture defect.
Residents should not be blamed automatically for damp and mould. Everyday activities generate
water vapour, but a healthy building should be capable of managing normal moisture through an
appropriate combination of heating, insulation, extraction and ventilation.
Cleaning mould safely
A small, isolated area of surface mould may sometimes be cleaned after the moisture source has
been corrected. Larger areas, recurrent mould, sewage-contaminated water damage or mould within
porous building materials may require professional assessment.
People with severe asthma, significant fungal allergy, aspergillosis or immune suppression
should avoid carrying out extensive mould removal themselves, because cleaning can release
spores and fragments into the air.
More practical guidance is available in our Housing & Environment Hub
.
When to seek medical advice
Contact your healthcare team when:
- asthma or breathlessness has become more difficult to control;
- you are waking at night because of cough, wheeze or chest tightness;
- you are needing reliever medication more frequently;
- you have recurrent chest infections or worsening sputum production;
- symptoms repeatedly improve away from the building and return after coming home;
- you have aspergillosis, fungal allergy or immune suppression and substantial mould exposure;
- the housing problem is causing serious anxiety, poor sleep or psychological distress.
Severe breathlessness, blue or grey lips, confusion, collapse, marked difficulty speaking or
a rapidly deteriorating asthma attack requires urgent medical help.
What remains uncertain?
Important gaps remain despite the strength of the overall evidence.
- There is no single health-based threshold that defines a safe total indoor fungal count.
- No one test captures all spores, fragments, allergens, microbial compounds and co-exposures.
- The health importance of a fungal genus depends on species, quantity and individual susceptibility.
- Associations observed in populations cannot prove the cause of every individual illness.
- More high-quality intervention studies are needed to establish which repairs deliver the greatest health benefit.
A Cochrane review of remediation in damp and mould-damaged buildings found some evidence that repairs can reduce respiratory symptoms, but also highlighted the limited number and variable quality of intervention studies.
The benchmark conclusion in 2026
The current scientific position can be summarised carefully:
Persistent dampness and mould in homes and workplaces are preventable environmental health
hazards. They are associated with asthma, respiratory symptoms, infections, allergic disease
and psychological distress, with greater concern for people who already have respiratory or
immune vulnerability.
The most important practical intervention remains the same: identify and correct the source of
moisture, dry the building and remove damaged or mould-contaminated material appropriately.
What has changed is our ability to examine exposure. New DNA-based studies show that indoor
fungal communities are complex, seasonal and highly variable between homes. This may eventually
allow better exposure standards and more targeted interventions, but the science is not yet at
the point where a commercial air sample can reliably predict an individual person’s health risk.
Further information and support
- Aspergillosis.org Housing & Environment Hub
- Damp Homes resources from Aspergillosis.org
- Reducing exposure to mould and Aspergillus at home
- Verified UK resources for damp, mould and health
- UK Government: understanding and addressing the health risks of damp and mould
- WHO guidelines for indoor air quality: dampness and mould
Selected evidence
- Hemmings SJ, Varaden D, Barnes J, et al. Diversity analysis of indoor and outdoor
fungal bioaerosols in UK households: a prospective, observational, longitudinal study.
Lancet Microbe. 2026;7:101379.
View the paper. - World Health Organization. WHO Guidelines for Indoor Air Quality: Dampness and
Mould. WHO Regional Office for Europe; 2009.
View the guideline. - Mendell MJ, Mirer AG, Cheung K, Tong M, Douwes J. Respiratory and allergic health
effects of dampness, mould, and dampness-related agents: a review of the epidemiologic
evidence. Environmental Health Perspectives. 2011;119:748–756.
PubMed. - Varga MK, et al. Childhood asthma and mould in homes: a meta-analysis.
Allergy. 2025.
PubMed. - Groot J, et al. Residential mould and dampness and the risk of respiratory tract
infections and respiratory symptoms in children: a systematic review and meta-analysis.
PubMed. - Wang J, Holm M, Dahlman-Höglund A, Janson C, et al. Dampness and mould over 20 years
and new onset of respiratory symptoms, asthma and rhinitis.
Journal of Hazardous Materials. 2026.
View the paper. - Gatto MR, Li A, Martino E, Bentley R. The effect of damp housing on psychological
distress: does respiratory health matter?
American Journal of Epidemiology. 2026;195:1292–1299.
PubMed. - Pakdehi M, Ahmadisharaf E, Suliman AA, Abdelrazig Y. Impacts of major floods on new
human respiratory health symptoms in indoor environments.
Journal of Cleaner Production. 2026;557:148247.
View the paper. - Wildman J, Shea A, Cascione V, et al. Mould susceptibility of bio-based insulation
materials in modern construction. npj Materials Degradation. 2026;10:29.
View the open-access review. - Sauni R, Verbeek JH, Uitti J, Jauhiainen M, Kreiss K, Sigsgaard T. Remediating
buildings damaged by dampness and mould for preventing or reducing respiratory tract
symptoms, infections and asthma. Cochrane Database of Systematic Reviews. 2015.
View the review.
Wildfire smoke and aspergillosis: protecting your lungs when air quality falls

Wildfires in parts of the UK and Europe can produce smoke that travels considerable distances. Even when a fire is many miles away, fine particles carried in the air may temporarily reduce local air quality.
People with aspergillosis, asthma, bronchiectasis, COPD or another chronic lung condition may be more sensitive to wildfire smoke. Smoke can irritate the airways and cause coughing, wheezing, chest tightness, breathlessness, sore eyes or a sore throat. It can also aggravate an existing respiratory condition.
Check the air quality where you live. UK residents can use the official Defra UK Air website. International websites such as IQAir can also provide useful local maps, forecasts and measurements.
What should people with lung conditions do?
UK health advice recommends reducing exposure to smoke and air pollution, particularly if you develop symptoms.
- Reduce strenuous outdoor activity. Exercise causes you to breathe more deeply and may increase the amount of smoke particles reaching your lungs.
- Stay indoors when smoke is affecting your area and keep doors and windows closed while the outdoor air quality is poor.
- Ventilate when conditions improve. Open windows when the smoke has cleared and outdoor air quality is better, particularly if the building is becoming hot.
- Take your usual medication as prescribed. Do not alter antifungal treatment, inhalers, steroids or other medicines unless advised by your healthcare team.
- Keep your reliever inhaler with you if one has been prescribed.
- Follow your asthma, COPD, bronchiectasis or respiratory action plan if you have one.
- Avoid adding more particles indoors. During a smoke episode, avoid smoking, wood-burning stoves, candles and other activities that create smoke.
- Keep cool and hydrated. Wildfires often occur during hot weather, which can place additional strain on people with heart, lung, kidney or other long-term conditions.
Do masks help?
A well-fitting particulate respirator such as an FFP2 or FFP3 mask may reduce the amount of fine particulate matter inhaled while outdoors. Loose-fitting surgical or fabric masks provide much less protection against fine smoke particles.
However, some people with significant lung disease may find tight-fitting masks uncomfortable or may become more breathless while wearing one. A mask should not be used as a reason to remain outdoors in heavy smoke. Reducing exposure remains the priority.
Does wildfire smoke increase Aspergillus infection?
Wildfire smoke is primarily a mixture of gases and very small particles produced by burning vegetation and other materials. Its immediate health effect is irritation and inflammation of the lungs and airways.
Smoke exposure does not necessarily mean that Aspergillus is growing in the lungs or that aspergillosis is worsening. However, people whose lungs are already damaged or inflamed may notice increased coughing, wheezing, mucus production or breathlessness.
Symptoms caused by smoke can resemble a respiratory flare-up. Contact your healthcare team if symptoms are new, unusually severe, persist after the air quality has improved, or are not controlled by your normal treatment plan.
When should you seek medical help?
Contact your GP, respiratory team or NHS 111 if:
- you develop new or worsening breathlessness, wheezing or chest tightness;
- you need your reliever inhaler more often than usual;
- your symptoms are not responding to your agreed treatment plan;
- your symptoms persist after the smoke has cleared; or
- you are concerned about a change in your condition.
Call 999 for severe breathing difficulty. This includes rapidly worsening breathlessness, being unable to speak normally, becoming confused or drowsy, developing blue or grey lips or skin, or an asthma attack that is not improving after using your reliever inhaler as directed.
Understanding air-quality alerts
The UK Daily Air Quality Index runs from 1 to 10:
- Low, 1–3: most people can continue normal outdoor activity.
- Moderate, 4–6: people with lung or heart conditions who develop symptoms should reduce strenuous outdoor activity.
- High, 7–9: people with lung conditions should reduce strenuous outdoor exertion, particularly if symptomatic.
- Very high, 10: people with lung or heart conditions and older adults should avoid strenuous physical activity.
People vary considerably in their sensitivity. Some people with severe asthma, bronchiectasis or aspergillosis may experience symptoms even when the overall air-quality rating is described as low or moderate. Your symptoms and personal respiratory action plan remain important.
Useful sources
- Defra UK Air: current air-quality measurements and alerts
- UK government health advice for the Daily Air Quality Index
- IQAir international air-quality map
- NHS advice about asthma and asthma attacks
This information is intended as general guidance and does not replace advice from your own healthcare team.
Learning to Live with Chronic Illness: Is It Really Like Grieving?

“How do you accept having a chronic illness? Is it a grieving process?”
It is one of the most thoughtful questions anyone living with a long-term health condition can ask.
Whether you have aspergillosis, bronchiectasis, severe asthma, COPD or another chronic illness, many people describe life as having two chapters: before illness and after illness.
Most of us grow up assuming our health will simply be there in the background. We make plans, book holidays, think about retirement, imagine spending time with grandchildren, travelling or enjoying hobbies. We rarely question whether our bodies will allow us to do these things.
Then, sometimes quite suddenly, life changes.
Perhaps the diagnosis follows weeks of investigations. Perhaps it comes after years of unexplained symptoms, repeated infections or unsuccessful treatments. Whatever the route, many people describe the feeling that the future they expected has quietly disappeared.
The physical symptoms may be obvious.
The emotional changes are often much harder to see.
That is why so many people describe living with chronic illness as a form of grief.
Grieving for the life you expected
When we hear the word grief, we usually think about losing someone we love.
However, grief can follow many different kinds of loss. A chronic illness may bring several losses, not necessarily all at once, but gradually over time.
You may grieve:
- the health you once took for granted
- your confidence in your body
- your independence or spontaneity
- work or career opportunities
- financial security
- hobbies and activities that have become more difficult
- changes in relationships or family roles
- the future you had imagined.
Perhaps you can no longer walk as far as you once did. Perhaps you worry about booking a holiday because you do not know how you will feel when the time comes. Perhaps you miss being the person everyone relied upon.
You may also miss the freedom of doing something without first considering your symptoms, medication, energy levels or access to healthcare.
These are genuine losses, even when nobody else can see them.
It is therefore entirely understandable that they may be accompanied by sadness, frustration, anger or fear.
The hidden or “side” griefs
One patient described something that many people immediately recognised: the “side griefs”.
These are the numerous, seemingly small losses that accompany chronic illness. Individually, they may not appear life-changing. Together, they can gradually reshape everyday life.
Perhaps you stop gardening because your breathing or energy will not allow it.
Perhaps you can no longer play with your grandchildren in the same way.
Perhaps you avoid crowded places because you are concerned about infection.
Perhaps you have become the person who always has to ask, “How far is the walk?” or “Will there be somewhere to sit?”
Perhaps an invitation that once brought excitement now brings several calculations: How will I travel? Will I have enough energy? What happens if I become unwell? Can I cancel at short notice?
None of these changes may appear dramatic to other people. Together, however, they can change how you see yourself and the life you live.
“Shouldn’t I be over this by now?”
Many people feel guilty about continuing to struggle emotionally after their diagnosis.
Friends and relatives may say:
“At least it is being treated.”
“You look well.”
“Try to stay positive.”
These comments are usually intended to be reassuring. However, living with a chronic illness is not simply about receiving treatment and then carrying on as before. It frequently requires further practical and emotional adjustment.
Some days that adjustment feels manageable. Other days it feels exhausting.
There is no correct timetable for coming to terms with a life-changing diagnosis.
Is there really a grieving process?
You may have heard of the “five stages of grief”: denial, anger, bargaining, depression and acceptance.
These ideas have helped many people put words around difficult emotions, but real life is rarely so orderly. People do not necessarily move neatly from one stage to the next, and not everyone experiences all of them.
You might feel angry when you are first diagnosed and then optimistic when treatment begins. You may feel settled for several months, only to become frightened again before a scan or clinic appointment.
A flare-up, hospital admission or change in treatment may bring back feelings you thought you had already dealt with.
This does not mean that you are going backwards.
It means you are responding to a changing situation.
Research into psychological adjustment to chronic disease suggests that people differ greatly in how they respond and that adjustment can vary across the course of an illness. There is no single emotional pathway that everyone must follow.
The emotional rollercoaster
Many people imagine that accepting a diagnosis is something that happens once.
Patients often describe something very different.
Living with chronic illness can feel like an emotional rollercoaster.
Good clinic appointments may be followed by disappointing ones.
One blood test brings relief. The next raises new questions.
A scan may show improvement, only for a new symptom to appear.
A treatment begins to work, but later causes side effects or needs to be changed.
One day you almost forget that you are ill. The next day, getting dressed may feel like hard work.
Hope and disappointment.
Confidence and uncertainty.
Good days and bad days.
This continual movement can be exhausting. Just as you begin to feel that life is becoming predictable again, something changes.
Many people say that they are emotionally tired as well as physically tired.
Good days and bad days
Good and bad days can affect how you understand your illness.
On a good day, you may wonder whether you have been too cautious or whether things are finally returning to normal.
On a bad day, you may fear that your illness is getting worse or that the improvement was never real.
Both reactions are understandable, but one day rarely tells the whole story.
Over time, many people learn to look for patterns over weeks or months rather than judging their health by one particularly good or difficult day.
A bad day does not necessarily mean that your condition is deteriorating.
A good day does not mean that the illness has disappeared.
One of the hardest skills is learning to enjoy a good day without spending it worrying about the next bad one. Another is remembering during a difficult day that how you feel today may not be how you feel tomorrow.
You do not adapt once
Perhaps the biggest misconception about chronic illness is that acceptance is a single event.
In reality, most people do not adapt once.
They adapt hundreds of times.
You adapt to the diagnosis.
Then to the first treatment.
Then to side effects.
Then to improvement.
Then to a setback.
You adapt to hospital appointments, new symptoms, reassuring results and worrying results.
You adapt to holidays that have to be cancelled and holidays that go better than expected.
You adapt to asking for help when you were previously independent and to saying no when you would once have said yes.
Every change asks you to adjust again.
This does not mean that you have failed to accept your illness. It reflects the reality of living with a condition that can fluctuate and change over time.
Acceptance is dynamic
Perhaps we should stop thinking of acceptance as something we either achieve or fail to achieve.
Acceptance is dynamic.
It changes as your illness changes, as treatments change and as life itself changes around you.
Every new situation may require another adjustment.
Acceptance is not a finish line. It is an ongoing process of recognising where you are now, adjusting your expectations and protecting the things that remain important to you.
Acceptance does not mean giving up.
It does not mean liking what has happened, pretending everything is fine or abandoning hope for better treatment.
It means recognising the reality of today without spending all your energy fighting the fact that the illness exists.
Many people describe a gradual shift. Instead of repeatedly asking:
“Why has this happened to me?”
they begin to ask:
“Given where I am today, how can I live as well as possible?”
The first question is entirely understandable, but it may never have a satisfying answer. The second may create choices, even when those choices are limited.
Not every day has to be positive
People living with chronic illness are often encouraged to “stay positive”.
The intention is usually kind. Sometimes, however, it can feel like another burden.
The reality is that some days are simply difficult.
You do not have to find a positive lesson in every setback.
You do not have to feel grateful every day.
You do not have to pretend that losing something important does not hurt.
Sometimes the healthiest response is simply to acknowledge:
“Today is hard.”
Tomorrow may be different.
When illness affects the whole family
Chronic illness rarely affects only the person who has been diagnosed.
Partners, children, relatives, friends and carers may also live with uncertainty, disrupted plans, additional responsibilities and concerns about the future.
A partner may not know whether to encourage activity or suggest rest. A relative may struggle to understand why someone can manage an outing one day but has to cancel plans the next. A carer may be carrying practical responsibilities while also trying to manage their own emotions.
Because symptoms fluctuate, family members may sometimes misread what is happening.
On a good day, they may assume that the illness is improving permanently. On a bad day, they may wonder why everything has suddenly changed again.
The person who is ill may then feel disbelieved, pressured or guilty. The family member may feel rejected, confused or unappreciated.
Nobody necessarily intends to hurt anyone, but frustration on both sides can make an already difficult situation feel worse.
Patients may feel guilty about cancelling plans, needing help or placing additional demands on those around them. Carers may feel guilty for becoming tired, impatient or resentful.
These feelings do not mean that anyone cares less. They usually mean that everyone is trying to adapt to a situation they did not choose.
Open communication can help. It may be useful to explain that symptoms fluctuate, that a good day does not mean the illness has disappeared, and that a cancelled plan is not a rejection.
It is equally important for carers and relatives to be honest about their own limits and to have time, support and interests that do not revolve entirely around illness.
Sometimes the most useful conversation is not about solving the problem. It is simply acknowledging:
“This is difficult for both of us, and neither of us is to blame.”
Both the person living with illness and the people supporting them may have to adapt hundreds of times. Doing that together requires patience, honesty and permission for everyone involved to have difficult days.
Families and friends supporting someone with chronic pulmonary aspergillosis may also find our guide to CPA for family and friends helpful.
Living with uncertainty
One of the hardest parts of chronic illness is often uncertainty.
You may not know how well a treatment will work, whether symptoms will improve or how much energy you will have tomorrow.
This unpredictability can make planning difficult. It may also make you feel that you cannot entirely trust your body.
Some people respond by constantly watching for symptoms or imagining everything that might go wrong. This is understandable, particularly after frightening experiences, but remaining permanently on alert can itself become exhausting.
Acceptance does not remove uncertainty. It can, however, help you concentrate more of your attention on what is happening today rather than trying to solve every possible version of the future.
The NHS guide to coping with change and uncertainty offers practical suggestions for focusing on the short term, recognising what is working and finding a new rhythm.
What helps people adapt?
There is no single method that works for everybody. However, research and the experiences of people living with chronic illness suggest that several things can help.
Understanding your condition
Reliable information can reduce some of the fear created by uncertainty. Understanding your condition, treatment and warning signs can help you feel more prepared and involved in decisions about your care.
At the same time, it is possible to become overwhelmed by searching for information. It may help to use a small number of trusted sources and discuss important questions with your healthcare team.
Managing energy rather than fighting it
Fatigue is not simply ordinary tiredness. It can affect concentration, confidence, relationships and emotional wellbeing as well as physical activity.
Learning to pace activity, prioritise important tasks and allow time for recovery is not laziness or surrender. It is a practical response to limited energy.
Our guide to managing fatigue and energy in aspergillosis and allergic fungal lung disease explains pacing, the “boom-and-bust” cycle and ways to use limited energy more effectively.
Talking honestly
Family and friends may want to help but may not understand what you need. They may see you on a relatively good day and assume that your illness has improved.
It can help to explain that symptoms fluctuate and that cancelling a plan does not mean you no longer care about the people involved.
You do not have to tell everyone everything. However, being honest with a few trusted people can reduce the effort involved in constantly pretending to be well.
Connecting with people who understand
Support from other patients can provide something that even loving relatives and skilled healthcare professionals may not always be able to offer: recognition from someone who has experienced something similar.
People may exchange practical ideas, but sometimes the most important benefit is simply hearing:
“I understand. I have felt that too.”
Our aspergillosis support groups and meetings provide welcoming online spaces for patients, carers and supporters. You can also explore the wider aspergillosis community and support hub.
Making room for difficult emotions
Trying to suppress every frightening, angry or unhappy thought can require enormous effort.
Approaches such as mindfulness and Acceptance and Commitment Therapy, usually shortened to ACT, do not ask people to pretend that difficult feelings are unimportant. Instead, they aim to help people make room for those feelings while continuing to take actions connected with what matters to them.
The aim is not to eliminate all distress. It is to reduce the extent to which distress controls every decision.
Our article on managing the stress of living with chronic disease explores grounding, mindfulness, breathwork and other ways of responding to prolonged stress.
Setting goals that belong to your life now
Goals can restore a sense of direction and control, but they may need to change.
A goal does not have to be dramatic. It might be:
- taking a short walk
- meeting a friend
- returning to a hobby in a modified form
- attending an important family occasion
- preparing one meal
- asking for help before reaching exhaustion.
Changing a goal is not necessarily failure. Sometimes it is how we preserve the part of the goal that matters most.
You are more than your diagnosis
One danger of chronic illness is that it can gradually take over your identity.
Medical appointments, symptoms, prescriptions and test results may begin to dominate everyday conversation. You may find yourself thinking about your life mainly in terms of what your body can no longer do.
But you are not simply “an aspergillosis patient”.
You may also be a parent, partner, grandparent, friend, musician, gardener, engineer, teacher, artist or volunteer.
Illness may change how you fulfil those roles. It does not erase them.
It can help to ask:
“What matters to me, and is there another way I can still be part of it?”
You may no longer be able to host a large family gathering, but perhaps you can spend quieter time with one or two people. You may no longer manage a full day in the garden, but you may still be able to grow something in a container near the house.
Adaptation is not always about doing less. Often, it is about protecting what matters most.
Where people find strength
Although the journey is different for everyone, many people eventually discover something that helps them continue moving forward.
For some, it is family or friendship.
For others, it is faith.
Some find strength in nature, creativity, humour, community, personal values or helping other people.
One patient shared these words with us:
“I have to constantly remind myself that God is sovereign and in all things He is working for good to bring me to a greater understanding of who He is.”
Not everyone shares the same beliefs, but many people describe finding comfort in something that feels larger than the illness itself. That source of strength is deeply personal, and there is no single right answer.
Hope changes too
When people are first diagnosed, hope often means hoping for a cure or a complete return to their previous life.
Over time, hope may take on different forms.
Hope may mean:
- having more good days than bad ones
- finding a treatment with fewer side effects
- walking a little further than last month
- reducing the need for steroid treatment
- taking a holiday
- seeing grandchildren grow up
- feeling useful and connected
- discovering that life still contains pleasure and meaning.
This is not necessarily a smaller or weaker form of hope.
It is hope that has adapted to reality while continuing to look forward.
When additional help may be needed
Sadness, frustration, anger and fear are understandable responses to chronic illness. However, sometimes emotional distress becomes persistent or begins to affect every part of life.
Consider speaking to your GP or healthcare team if you are:
- feeling low or hopeless most of the time
- experiencing frequent panic or overwhelming anxiety
- withdrawing from everyone around you
- unable to sleep because of worry
- losing interest in nearly everything you previously valued
- finding that distress is making it difficult to manage medication, food or basic daily care.
Seeking psychological support does not mean that your physical symptoms are “all in your head”. Chronic physical illness places genuine demands on emotional wellbeing, and receiving help with those demands is part of caring for the whole person.
The NHS has practical guidance on looking after your mental health when living with physical illness. Its Every Mind Matters service also provides advice about stress, anxiety, low mood and sleep.
You are not alone
If you are finding it difficult to accept a chronic illness, you are in very good company.
Almost everyone living with a long-term condition experiences periods of sadness, frustration, fear or grief.
These feelings do not mean you are weak.
They do not mean you are failing.
They mean you are adapting to one of life’s greatest challenges.
Not once, but over and over again.
You may adapt hundreds of times during your journey:
To good news.
To bad news.
To better days.
To worse days.
To new medication.
To unexpected side effects.
To a reassuring scan.
To a worrying blood result.
To holidays that happen.
To holidays that have to be cancelled.
To the loss of something you valued.
To the discovery of something new that brings you joy.
Acceptance is not a finish line.
It is a lifelong process of adapting to change while holding on to the things that matter most.
Life may not be the one you planned.
But it can still be a life filled with love, purpose, hope and moments of genuine happiness.
Further support
Living with chronic illness can sometimes feel overwhelming, but you do not have to face it alone.
You may find it helpful to talk to:
- your GP
- your respiratory or specialist team
- a trusted friend or relative
- a counsellor, psychologist or NHS Talking Therapies service
- other people living with a similar condition.
For aspergillosis-specific support, visit our support groups and meetings page.
References and further reading
- Stanton AL, Revenson TA, Tennen H. Health psychology: psychological adjustment to chronic disease. Annual Review of Psychology. 2007;58:565–592. View on PubMed.
- Bonanno GA, Westphal M, Mancini AD. Resilience to loss and potential trauma. Annual Review of Clinical Psychology. 2011;7:511–535. View on PubMed.
- Graham CD, Gouick J, Krahé C, Gillanders D. A systematic review of the use of Acceptance and Commitment Therapy in chronic disease and long-term conditions. Clinical Psychology Review. 2016;46:46–58. View on PubMed.
- Herbert MS, Dochat C, Wooldridge JS, et al. Technology-supported Acceptance and Commitment Therapy for chronic health conditions: a systematic review and meta-analysis. Behaviour Research and Therapy. 2022;148:103995. View on PubMed.
This article provides general information and emotional support. It is not a substitute for individual medical or psychological advice. Please speak to your GP, specialist team or another qualified healthcare professional about your own circumstances.
Aspergillosis Research Update: ICU Infections, Immune Defences and Antifungal Treatment

Published: July 2026
Medical research into aspergillosis continues to advance rapidly, with new studies appearing almost every week. Some confirm what doctors already suspected, while others introduce new ideas about how the body fights fungal infections or how treatment might improve in the future.
This week’s research includes a major international review of invasive aspergillosis in intensive care, encouraging real-world results for the antifungal drug isavuconazole, and two laboratory studies suggesting that specialised immune cells called macrophages may play an even greater role in protecting the lungs than previously appreciated.
None of these studies changes current treatment recommendations immediately. Together, however, they highlight an important direction in aspergillosis research: understanding not only how to kill the fungus, but also how to strengthen the body’s own immune defences.
A major international review confirms the burden of invasive aspergillosis in intensive care
A systematic review and meta-analysis combined results from 56 observational studies involving 15,385 intensive care patients. Among these patients, 2,381 cases of invasive pulmonary aspergillosis, or IPA, were identified.
The researchers estimated that IPA occurred in approximately 11.9% of the critically ill patients included in the studies. The estimated incidence increased to 15% among patients receiving mechanical ventilation.
Mortality among patients diagnosed with IPA was high:
- 59.6% overall mortality
- 61.9% mortality among mechanically ventilated patients
Factors associated with an increased risk of developing IPA included:
- immunosuppression;
- blood cancers and other malignancies;
- corticosteroid use before admission to intensive care;
- chronic lung, kidney, liver or heart disease;
- mechanical ventilation;
- vasopressor treatment;
- and renal replacement therapy.
What does this mean?
This study reinforces that invasive aspergillosis remains a serious complication in selected critically ill patients.
However, the results should not be interpreted as meaning that approximately one in eight people admitted to intensive care will develop aspergillosis. The authors state that the evidence predominantly reflects COVID-19-associated pulmonary aspergillosis, commonly known as CAPA.
Many of the identified risk factors, such as mechanical ventilation, vasopressor treatment and renal replacement therapy, are also signs that a patient is already extremely unwell. The study therefore identifies associations but cannot prove that these treatments independently cause aspergillosis.
The authors conclude that targeted screening and tailored antifungal strategies in high-risk patients deserve prospective evaluation. They do not claim that universal screening or preventive antifungal treatment has already been shown to improve survival.
Read the paper record on PubMed
Real-world evidence continues to support isavuconazole
Another study examined how well isavuconazole performs in routine clinical practice among people with blood cancers who develop serious invasive mould infections.
The retrospective study included 84 adults treated at two hospitals in China between 2022 and 2025:
- 62 had invasive aspergillosis;
- 14 had mucormycosis;
- 8 had mixed mould infections.
The main measure of success was assessed after six weeks. To count as successful treatment, the patient had to survive, show clinical or radiological improvement and avoid stopping treatment because of failure or toxicity.
The overall six-week treatment success rate was 59.5%. Among patients with aspergillosis, treatment success was higher, at 69.4%.
Only four patients experienced recorded drug-related adverse effects, and one stopped treatment because of vomiting.
What does this mean?
These findings are reassuring because they reflect routine clinical practice rather than the more controlled circumstances of a clinical trial.
The study found that patients receiving isavuconazole alone appeared to have better outcomes than those receiving combination antifungal treatment. However, this result must be interpreted cautiously.
Doctors commonly reserve combination therapy for patients who are more severely ill, have failed previous treatment, have mixed infections or are suspected of having resistant disease. The poorer outcomes in the combination-treatment group may therefore reflect the severity of the patients’ infections rather than harm caused by combining antifungal medicines.
This is known as confounding by indication. Because the patients were not randomly assigned to treatment, the study cannot establish that monotherapy is superior to combination treatment.
Overall, the study adds confidence that isavuconazole can be an effective and generally well-tolerated treatment for invasive aspergillosis in patients with haematological malignancies. It does not show that isavuconazole is better than other antifungal medicines, and it does not apply directly to chronic pulmonary aspergillosis, ABPA or Aspergillus bronchitis.
Read the paper record on PubMed
Could strengthening lung macrophages help prevent invasive aspergillosis?
Perhaps the most scientifically intriguing study this week did not test a new antifungal drug.
Instead, researchers investigated whether they could improve the ability of the lung’s own immune cells to eliminate Aspergillus fumigatus before infection became established.
The study focused on alveolar macrophages. These specialised immune cells live inside the air sacs of the lungs and are among the first cells to encounter inhaled Aspergillus spores.
Using a stem-cell transplant mouse model and an unusually low dose of Aspergillus spores intended to resemble everyday exposure, the researchers found that alveolar macrophages played a crucial role in protecting against invasive aspergillosis during the earliest stages of infection.
The researchers then tested whether macrophage function could be improved using macrophage colony-stimulating factor, or M-CSF.
M-CSF treatment:
- improved macrophage migration;
- enhanced phagolysosomal function;
- increased fungal killing;
- preserved lung tissue;
- reduced inflammatory cytokines;
- and protected mice against lethal invasive aspergillosis.
The researchers also tested primary human alveolar macrophages and found that M-CSF improved several of the same antifungal functions.
Importantly, the protective effect disappeared when alveolar macrophages were removed. This provides strong experimental evidence that the macrophages themselves were responsible for much of the benefit.
What does this mean?
This research suggests that tissue-resident macrophages may play an especially important role during the first hours after Aspergillus spores reach the lungs.
It also supports the wider idea of host-directed therapy: treatments designed to strengthen the patient’s immune response rather than attacking the fungus directly.
However, this study was carried out mainly in mice and has been published as a preprint. It has not yet completed formal peer review.
M-CSF is therefore not an established treatment for aspergillosis. Researchers would need to establish appropriate dosing, safety and effectiveness in people, particularly because stimulating immune activity after stem-cell transplantation could potentially affect inflammation, graft-versus-host disease and other immune processes.
Tuberculosis may affect immune defences as well as damaging the lungs
People who have previously had pulmonary tuberculosis are at increased risk of developing chronic pulmonary aspergillosis, or CPA.
The usual explanation is structural lung damage. Tuberculosis may leave behind cavities, scarring, bronchiectasis and damaged airways, creating an environment in which Aspergillus can persist.
A new laboratory study suggests that there may also be an immunological component.
The researchers studied a mycobacterial cell-wall molecule called lipoarabinomannan, or LAM. This molecule is known to interfere with some of the cellular pathways used by macrophages to respond to infection.
Bone-marrow-derived macrophages were exposed to two forms of LAM and then challenged with swollen Aspergillus fumigatus conidia.
Exposure to LAM:
- increased macrophage death;
- increased inflammatory cytokine release, particularly IL-1β;
- and reduced the ability of macrophages to kill Aspergillus conidia during the first six hours of infection.
The reduction in fungal killing was demonstrated using both colony-counting methods and time-lapse fluorescence microscopy.
What does this mean?
This study provides a plausible biological mechanism through which mycobacterial infection might interfere with early antifungal immune responses.
It does not, however, prove that this mechanism causes CPA after tuberculosis.
The experiments were conducted in laboratory-grown macrophages. They do not show that LAM remains present in the lungs for months or years after tuberculosis, nor that macrophages from people with previous tuberculosis behave in the same way.
The findings therefore do not replace the established structural explanation linking tuberculosis and CPA. Instead, they raise the possibility that lung damage and altered local immunity may work together.
Read the paper record on PubMed
A common theme emerges: macrophages matter
Although these studies examined different questions, two independent research groups reached complementary conclusions.
One study found that strengthening macrophage activity improved fungal killing and survival. The other found that disrupting macrophage activity reduced fungal killing.
Together, they support an emerging view that alveolar macrophages may be central to determining whether inhaled Aspergillus spores are cleared rapidly or allowed to develop into disease.
This does not reduce the importance of neutrophils, antifungal medicines or structural lung damage. Instead, it adds a more detailed understanding of what may happen during the earliest stages of fungal exposure.
Future advances in aspergillosis treatment may therefore involve both:
- better drugs that attack Aspergillus directly;
- and treatments that help the immune system respond more effectively.
What does this mean for people living with aspergillosis?
For most patients currently receiving treatment, these studies do not change day-to-day management.
Antifungal medicines remain the foundation of treatment for invasive and chronic Aspergillus infection. Patients should continue following the advice of their respiratory, infectious-diseases or specialist aspergillosis team.
These studies nevertheless provide encouraging evidence that aspergillosis research is progressing across several fronts:
- improving recognition of invasive aspergillosis in intensive care;
- evaluating how existing antifungal treatments perform in routine practice;
- understanding why some people are more vulnerable to Aspergillus than others;
- and exploring whether the immune system itself could become a future treatment target.
Progress is often gradual, and laboratory findings do not always lead to successful treatments. However, each study adds another piece to the puzzle and helps researchers move towards more effective and more personalised approaches to aspergillosis.
References
- Zhou Z, Luo B, Zhang X, et al. Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials. Published 10 July 2026. PubMed. DOI.
- Zhang J, Xu M, Mao J, et al. Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks. Antimicrobial Agents and Chemotherapy. Published 6 July 2026. PubMed. DOI.
- Sheta D, Mokhtari Z, Strobel M, et al. M-CSF-stimulated alveolar macrophages safeguard from invasive aspergillosis. bioRxiv. Preprint published 9 July 2026. DOI and preprint.
- Gonzales-Huerta LE, Williams TJ, Aljohani R, et al. Mycobacterial lipoarabinomannan negatively interferes with macrophage responses to Aspergillus fumigatus in vitro. PLOS ONE. 2026;21(7):e0351935. PubMed. DOI.
This article summarises newly published research for patients and non-specialist readers. It does not replace individual medical advice from a qualified healthcare professional.
How to Remove Mould from Your Washing Machine and Stop It Coming Back

Mould inside a washing machine is common, particularly in front-loading machines. It often develops in the rubber door seal, detergent drawer, filter and other areas where moisture and detergent residue collect.
For most people, a small amount of washing-machine mould is mainly an unpleasant cleaning problem. However, people living with aspergillosis, severe asthma, allergies or other long-term lung conditions may reasonably want to reduce avoidable mould exposure in the home.
The most effective approach is not only to remove visible mould, but also to keep the machine dry and clean enough to prevent it returning.
Key points
- Mould grows where moisture, detergent residue and dirt remain inside the machine.
- The rubber door seal and detergent drawer are the most common problem areas.
- Use gentle cleaning methods that avoid spraying mould spores or strong chemicals into the air.
- Never mix bleach with vinegar, acidic cleaners, ammonia or other cleaning products.
- Leaving the door and detergent drawer open between washes can greatly reduce recurrence.
Why does mould grow inside washing machines?
Modern washing machines often use less water and lower washing temperatures. This saves energy, but it can also allow detergent residue, fabric conditioner, skin oils, dirt and moisture to build up inside the machine.
Mould is more likely to develop when:
- the door is closed immediately after a wash;
- wet laundry is left inside the drum;
- mostly cool or eco washes are used;
- too much detergent or fabric conditioner is added;
- the rubber seal is not wiped or allowed to dry;
- the detergent drawer or filter is rarely cleaned;
- the machine is kept in a poorly ventilated room.
Where to check for mould
Mould may not always be immediately visible. Check the following areas carefully:
- Rubber door seal: pull back the folds and inspect underneath.
- Detergent drawer: remove it if possible and check the compartment behind it.
- Drum: look around the door opening and drainage holes.
- Filter: check the manufacturer’s instructions before opening it.
- Drainage area: persistent odours may indicate residue or stagnant water deeper inside the machine.
Before you start cleaning
Check the washing machine manufacturer’s instructions first. Different manufacturers recommend different cleaning products, temperatures and maintenance programmes.
To reduce exposure while cleaning:
- open a window or improve ventilation;
- wear household cleaning gloves;
- avoid leaning directly over mouldy areas;
- use damp disposable cloths rather than dry brushing;
- avoid scraping or scrubbing so vigorously that material is dispersed into the air;
- ask someone else to clean the machine if mould exposure usually worsens your breathing.
Some people with aspergillosis or severe respiratory disease may choose to wear a well-fitting FFP2 or FFP3 mask during mould cleaning. A mask does not replace ventilation or careful cleaning methods.
How to clean mould from the rubber door seal
- Switch off the washing machine.
- Gently pull back the folds of the rubber seal.
- Remove any trapped lint, hair, tissues or other debris.
- Wipe the area using a damp cloth and a cleaning product approved by the machine manufacturer.
- Pay particular attention to the lower part of the seal, where water often collects.
- Use a clean damp cloth to remove any remaining cleaning product.
- Dry the seal thoroughly.
Black staining may remain even after mould has been removed. Persistent staining does not always mean that mould is still actively growing, but damaged or deeply contaminated seals may need replacing.
How to clean the detergent drawer
- Remove the drawer according to the manufacturer’s instructions.
- Wash it with warm water and washing-up liquid.
- Use a small brush for narrow areas, taking care not to flick residue into the air.
- Wipe the compartment where the drawer sits.
- Rinse and dry the drawer before replacing it.
Using too much detergent or fabric conditioner can encourage residue to collect in this area. Follow the dosing instructions for your detergent and local water hardness.
Cleaning the filter
Many washing machines have a filter behind a small panel near the bottom of the machine. This may collect lint, hair, coins and other debris.
Before opening it:
- read the manufacturer’s instructions;
- switch off and unplug the machine;
- place towels or a shallow tray underneath, as water may escape;
- allow hot water to cool before opening the filter.
Clean the filter, remove debris and replace it securely. A blocked or dirty filter can contribute to poor drainage and unpleasant smells.
Run a maintenance wash
After cleaning the visible parts of the machine, run the manufacturer’s drum-clean or maintenance programme.
If the machine does not have a dedicated cleaning cycle, the manufacturer may recommend an empty hot wash. Use only a cleaning product that is suitable for your particular machine.
Do not assume that adding more cleaner will work better. Excessive detergent or cleaning product may leave additional residue behind.
Avoid mixing cleaning chemicals
Important safety warning
Never mix bleach with vinegar, limescale remover, toilet cleaner, ammonia or other household cleaning products.
Mixing bleach with acidic products can release chlorine gas, which can cause serious breathing difficulties and may require urgent medical attention.
Use one product at a time, follow the label instructions and rinse surfaces before using any different product.
How to stop washing-machine mould coming back
Keeping the machine dry between washes is often more effective than repeatedly carrying out deep cleaning.
- Remove laundry promptly when the cycle finishes.
- Leave the washing-machine door slightly open between washes.
- Leave the detergent drawer open so it can dry.
- Wipe moisture from the door seal, particularly from the lower folds.
- Use the correct amount of detergent.
- Reduce or avoid fabric conditioner if residue repeatedly builds up.
- Run the manufacturer’s maintenance cycle regularly.
- Clean the drawer, seal and filter routinely.
- Make sure the room is adequately ventilated.
How often should the machine be cleaned?
There is no single schedule suitable for every household. A machine used daily may need more frequent attention than one used only occasionally.
As a practical guide:
- wipe and check the door seal every week or two;
- clean the detergent drawer approximately once a month;
- run a maintenance wash according to the manufacturer’s advice;
- check the filter every few months, or sooner if drainage becomes slow or the machine smells.
Clean the machine sooner if you notice visible mould, slime, residue or a persistent musty smell.
When should the door seal be replaced?
Replacing the rubber door seal may be more effective than repeated cleaning if:
- the seal is cracked, torn or misshapen;
- mould is deeply embedded in the rubber;
- water repeatedly collects because the seal is damaged;
- the machine leaks;
- a persistent smell remains after thorough cleaning.
A competent appliance engineer may be able to replace the seal without replacing the whole washing machine.
When might the washing machine need professional attention?
Consider contacting the manufacturer or an appliance engineer if:
- the machine does not drain properly;
- stagnant water remains inside;
- the smell returns immediately after cleaning;
- mould appears to be growing behind inaccessible panels;
- the machine leaks;
- the seal or internal pipework needs replacing.
Is washing-machine mould dangerous for people with aspergillosis?
Finding mould in a washing machine does not necessarily mean that your home contains unusually high levels of airborne mould. Washing machines are naturally damp environments, and small amounts of mould are common.
However, people with aspergillosis or other significant respiratory conditions may wish to take reasonable precautions, particularly when disturbing visible mould.
Try to avoid:
- dry brushing;
- scraping large mouldy areas;
- using sprays that create a fine mist;
- mixing cleaning chemicals;
- remaining in a poorly ventilated room while strong products are being used.
If cleaning mould reliably causes coughing, wheezing, chest tightness or breathlessness, ask someone else to do the cleaning where possible.
When to seek medical advice
Seek medical advice if you develop a persistent worsening of respiratory symptoms after mould exposure, particularly if you have aspergillosis, severe asthma, bronchiectasis or another chronic lung condition.
Call 999 or seek urgent medical help if exposure to cleaning chemicals causes severe breathlessness, chest pain, confusion, collapse or difficulty speaking in full sentences.
Frequently asked questions
Can I use bleach in my washing machine?
Only use bleach if the washing-machine manufacturer states that it is safe for your model. Bleach can damage some rubber seals, metal parts and internal components.
Never mix bleach with vinegar or any other cleaning product.
Can I use vinegar?
Some manufacturers advise against regular vinegar use because concentrated acids may damage rubber seals or internal components. Check the instructions for your machine before using it.
Does a hot wash kill mould?
A hot maintenance wash may help reduce microorganisms and remove detergent residue, but it may not remove mould that is deeply embedded in a damaged rubber seal. Physical cleaning and drying are still important.
Should I replace the machine if there is mould in the seal?
Usually not. The seal can often be cleaned or replaced. Replacing the entire machine is generally only necessary if there is extensive inaccessible contamination, repeated drainage problems or the cost of repair is not economical.
Should I keep the door open all the time?
Leaving the door slightly open helps moisture evaporate. However, consider the safety of children and pets, who may climb into an open machine. Keep the laundry area secure where necessary.
Does washing at low temperatures cause mould?
Low-temperature washes can contribute to residue building up inside the machine, particularly if too much detergent or fabric conditioner is used. Regular maintenance cycles can help control this.
Related information
- Choosing a face mask for protection from dust and mould
- Getting help with damp and mould in rented housing
- Indoor air quality and aspergillosis
- Damp and mould in the home
Always follow the cleaning and maintenance instructions supplied by the manufacturer of your washing machine.
Why Can an Asthma Drug Help ABPA? Understanding Xolair (Omalizumab)

Originally published: 8 July 2026
Last reviewed: 8 July 2026
Many people diagnosed with Allergic Bronchopulmonary Aspergillosis (ABPA) are surprised when their specialist suggests Xolair (omalizumab).
"I thought Xolair was an asthma medication. How can it possibly help a fungal lung disease?"
It is a very reasonable question.
The answer is that ABPA is not simply an infection caused by Aspergillus. It is an allergic lung disease in which the immune system overreacts to the presence of Aspergillus in the airways.
Xolair does not kill the fungus. Instead, it helps calm the allergic immune response that drives many of the symptoms of ABPA.
Key Points
- Xolair (omalizumab) is a biologic medicine originally developed for severe allergic asthma.
- Many people with ABPA also have severe allergic asthma.
- Omalizumab targets IgE, an antibody involved in allergic inflammation.
- In the UK, omalizumab is usually prescribed through NHS severe asthma pathways, not because ABPA itself is a licensed indication.
- Treating severe allergic asthma can also improve ABPA because the two conditions share important allergic immune pathways.
- Biosimilar versions of omalizumab are now becoming available, which may make biologic treatment more accessible for eligible patients.
Understanding ABPA
Everyone breathes in Aspergillus spores every day.
For most people, this causes no illness. In people with ABPA, however, the immune system reacts too strongly. Instead of ignoring the spores, it launches an exaggerated allergic response.
This can cause:
- airway inflammation
- wheezing
- coughing
- breathlessness
- excessive mucus production
- repeated flare-ups
- gradual lung damage if poorly controlled.
In many patients, the allergic response causes more problems than the fungus itself.
That is why doctors may treat both the amount of fungus in the airways and the immune system's overreaction to it.
What Does IgE Have To Do With ABPA?
One of the key parts of allergic disease is an antibody called Immunoglobulin E, usually shortened to IgE.
Think of IgE as part of the body's allergy alarm system.
In ABPA, the immune system produces IgE against Aspergillus. This can trigger immune cells to release chemicals that cause allergic inflammation. These chemicals narrow the airways, increase mucus production and attract other inflammatory cells, including eosinophils.
Doctors often measure total IgE because it is important in diagnosing and monitoring ABPA.
How Does Xolair Work?
Xolair (omalizumab) is a biologic medicine. Biologics are targeted treatments designed to block specific parts of the immune system.
Omalizumab attaches to free IgE antibodies before they can trigger the allergic cascade.
As a result:
- allergic inflammation may be reduced
- asthma symptoms may improve
- flare-ups may become less frequent
- some patients may be able to reduce oral steroid treatment
- quality of life may improve.
Xolair does not kill Aspergillus.
Instead, it reduces the body's excessive allergic response to the fungus.
Why Was I Offered An Asthma Drug?
This is one of the most common questions patients ask.
Although ABPA is a distinct condition, many people with ABPA also have severe allergic asthma. The two conditions share many of the same allergic immune pathways, particularly those involving IgE.
In the UK, omalizumab is not currently licensed specifically for ABPA.
Many patients receive omalizumab because they meet NHS eligibility criteria for severe allergic asthma. When the allergic asthma improves, the ABPA may also improve because both conditions are driven by overlapping allergic inflammation.
In other words, the treatment is not aimed at killing Aspergillus. It is aimed at reducing the allergic inflammation that contributes to both severe asthma and ABPA.
Why Can't Everyone With ABPA Have Xolair?
This is an important question.
In the NHS, access to omalizumab is usually based on nationally agreed eligibility criteria for licensed conditions such as severe allergic asthma. A diagnosis of ABPA alone does not usually make someone eligible for omalizumab treatment.
This does not mean omalizumab cannot help some people with ABPA. It means that NHS prescribing is guided by licensing, NICE recommendations, commissioning arrangements and clinical judgement.
Your respiratory specialist will consider your asthma severity, ABPA history, IgE levels, previous treatments, steroid exposure, flare-up frequency and overall health when deciding whether a biologic medicine may be appropriate.
Why Aren't Antifungal Drugs Enough?
Antifungal medicines such as itraconazole or voriconazole reduce the amount of Aspergillus growing in the airways.
However, reducing the fungus does not always completely switch off the allergic immune response.
Different treatments target different parts of the disease:
| Treatment | Main purpose |
|---|---|
| Antifungal medicines | Reduce the amount of Aspergillus |
| Corticosteroids | Reduce widespread inflammation |
| Biologics such as omalizumab | Target specific allergic pathways |
| Airway clearance | Help remove mucus from the lungs |
These treatments often work together rather than replacing one another.
Why Have Steroids Been Used For So Long?
For many years, oral corticosteroids such as prednisolone have been a main treatment for ABPA.
Steroids are often effective at controlling inflammation quickly, but prolonged or repeated courses can cause significant side effects, including:
- weight gain
- diabetes
- osteoporosis
- cataracts
- mood changes
- increased infection risk
- adrenal suppression or adrenal insufficiency.
One reason biologics are important is that they may help some suitable patients reduce their need for long-term oral steroids under specialist supervision.
Does Xolair Help Everyone?
No.
Some patients experience major improvements. Others notice more gradual changes. A small number may gain little benefit and may be better suited to a different biologic medicine.
Published studies and specialist-centre experience suggest that some patients with ABPA treated with omalizumab may experience:
- fewer exacerbations
- better asthma control
- reduced oral steroid requirements
- improved quality of life.
Because ABPA is relatively uncommon, much of the evidence comes from case series, observational studies, smaller trials and systematic reviews rather than the very large trials often performed for common diseases.
Why Isn't Xolair Licensed Specifically For ABPA?
This can be confusing for patients.
Being "not licensed for ABPA" does not necessarily mean there is no evidence that omalizumab can help. It means that the medicine has not gone through the formal licensing process for ABPA as a specific indication.
Licensing a medicine for a new condition usually requires large, expensive clinical trials. ABPA is a relatively uncommon disease, which makes such studies difficult to organise and fund.
There is also less commercial incentive now that omalizumab biosimilars are becoming available. No single manufacturer may have a strong reason to fund large registration trials for an additional ABPA indication.
As a result, the scientific evidence and clinical experience have grown faster than the formal licensing process.
Why Is Omalizumab Back In The News?
Omalizumab itself is not new. It has been used for severe allergic asthma for more than twenty years.
What is new is the increasing availability of biosimilar omalizumab.
Biosimilars are highly similar versions of an existing biologic medicine. They must show comparable quality, safety and effectiveness before approval.
This matters because biologic medicines are expensive. Increased competition from biosimilars is expected to reduce costs over time.
Lower costs may improve access for patients who meet NHS eligibility criteria and may also increase research interest in biologic treatment for conditions such as ABPA.
It is important not to overpromise: biosimilars do not automatically mean that everyone with ABPA will be offered omalizumab. NHS access will still depend on eligibility criteria, clinical assessment and local pathways.
Are There Other Biologics?
Yes.
Omalizumab was the first biologic widely used in allergic asthma and has been used in selected patients with ABPA. Newer biologics target different parts of the allergic inflammatory pathway.
Depending on an individual's disease pattern, specialists may consider medicines such as:
- mepolizumab
- benralizumab
- dupilumab
- tezepelumab.
Research is continuing to determine which patients are most likely to benefit from each biologic.
Questions You May Wish To Ask Your Specialist
- Why do you think omalizumab is appropriate for me?
- Am I being considered for this because of severe allergic asthma, ABPA, or both?
- How long before we know whether it is working?
- Will I still need antifungal treatment?
- Could this help reduce my oral steroid dose?
- What side effects should I watch for?
- Would another biologic be more suitable for my type of inflammation?
The Bottom Line
Xolair (omalizumab) was originally developed for severe allergic asthma, but it can also help some people with ABPA because ABPA is strongly driven by allergic immune inflammation.
In the NHS, omalizumab is usually prescribed through severe asthma pathways rather than because ABPA itself is a licensed indication.
It is not an antifungal drug and it is not a cure for ABPA. Instead, it is part of a modern treatment approach that may include antifungal medicines, airway clearance, corticosteroids, monitoring and biologic therapy in selected patients.
With biosimilar omalizumab becoming available and newer biologics continuing to emerge, treatment options for severe allergic lung disease are changing. For people living with ABPA, this is an important and rapidly developing area of care.
Related Articles
- Understanding Biologic Treatments for Aspergillosis
- ABPA: A Complete Patient Guide
- Understanding Steroids, Cortisol, ACTH and Adrenal Suppression
- Can Biologics Reduce the Need for Steroids?


